6 October 2023 in Proceedings of the National Academy of Sciences
Despite much effort, antibody therapies for Alzheimer’s disease (AD) have shown limited efficacy. Challenges to the rational design of effective antibodies include the difficulty of achieving specific affinity to critical targets, poor expression, and antibody aggregation caused by buried charges and unstructured loops. To overcome these challenges, we grafted previously determined sequences of fibril-capping amyloid inhibitors onto a camel heavy chain antibody scaffold. These sequences were designed to cap fibrils of tau, known to form the neurofibrillary tangles of AD, thereby preventing fibril elongation. The nanobodies grafted with capping inhibitors blocked tau aggregation in biosensor cells seeded with postmortem brain extracts from AD and progressive supranuclear palsy (PSP) patients. The tau capping nanobody inhibitors also blocked seeding by recombinant tau oligomers. Another challenge to the design of effective antibodies is their poor blood–brain barrier (BBB) penetration. In this study, we also designed a bispecific nanobody composed of a nanobody that targets a receptor on the BBB and a tau capping nanobody inhibitor, conjoined by a flexible linker. We provide evidence that the bispecific nanobody improved BBB penetration over the tau capping inhibitor alone after intravenous administration in mice. Our results suggest that the design of synthetic antibodies that target sequences that drive protein aggregation may be a promising approach to inhibit the prion-like seeding of tau and other proteins involved in AD and related proteinopathies.
24 April 2024 in Journal of the American Chemical Society
4 December 2025 in ChemRxiv
Herein, we introduce an operationally simple approach for the direct covalent modification of metalloenzymes via Au(III)-mediated S-arylation chemistry. Using a model class of rubredoxin metalloenzymes containing Fe or Ni in the tetrathiolate active site, we show that these biomolecules can be site-selectively tagged with a variety of abiotic functional groups by leveraging a cysteine residue positioned distal to the active site. The bioconjugation proceeds under mild aqueous conditions, rapidly, and in quantitative yields, and most importantly without perturbing the structural or functional integrity of the enzyme, which normally can occur through adventitious demetallation of the active site. Detailed structural studies, including the first reported X-ray crystal structure of a cysteine-arylated metalloprotein, illuminate a clear preference for regioselective arylation at solvent-exposed cysteine residues, offering a blueprint for predictable and programmable bioconjugation in complex biomolecules. This work demonstrates a unique power of “backgroundless” Au(III) arylation chemistry, rendering site-selective bioconjugation of some of the most delicate biomolecules.
26 July 2026 in Bioconjugate Chemistry
Herein, we demonstrate how Au(III) organometallic chemistry offers the potential to streamline the generation of constrained peptide tricycles. By leveraging the chemoselectivity and ultrafast kinetics of tetrametallic Au(III)-based aryl reagents toward cysteine (Cys) bioconjugation, we have constructed a small library of constrained peptide tricycles. These tricycles can be synthesized and isolated in 25-55% yields from various tetracysteine-containing linear peptides. In all cases, tricyclization conversion occurs quantitatively under five min at sub-mM concentrations of the target peptide and proceeds under varied distributions of the four Cys residues in the target peptide sequence. Furthermore, by constraining various linear peptides around the aryl core of tetraphenylethylene, a common solid-state luminogen, we generate fluorescent macrocycles with robust solution-state emissive profiles. We evaluated the innate affinity of these fluorescent hybrid peptides toward cells, finding that they behave as highly selective luminogenic cell markers of cellular debris.